The study and its comparison
Ninety-nine adults with biopsy-confirmed NASH were randomized to silymarin 700 mg three times daily or placebo for 48 weeks. The primary endpoint was at least a 30-percent reduction in the activity score. [1]
That endpoint occurred in 32.7 percent versus 26.0 percent, a nonsignificant difference. Secondary histology and stiffness measures suggested a fibrosis benefit that the authors said required confirmation. [1]
What the finding establishes
A positive secondary endpoint does not convert a negative primary result into an established treatment. The single-center study was small, and funding and conflicts were not established from the abstract. It does not validate retail liver-detox mixtures or replacement of clinical management. [1]
A hypothetical distinction
Imagine a trial misses its main endpoint but one secondary measure improves. That is a research signal requiring confirmation.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.